191 related articles for article (PubMed ID: 29589471)
1. De-escalating treatment in the adjuvant setting in HER2-positive breast cancer.
Barroso-Sousa R; Exman P; Tolaney SM
Future Oncol; 2018 Apr; 14(10):937-945. PubMed ID: 29589471
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant trastuzumab: a 10-year overview of its benefit.
Lambertini M; Pondé NF; Solinas C; de Azambuja E
Expert Rev Anticancer Ther; 2017 Jan; 17(1):61-74. PubMed ID: 27883296
[TBL] [Abstract][Full Text] [Related]
3. Optimal adjuvant treatment for patients with HER2-positive breast cancer in 2015.
Zardavas D; Fouad TM; Piccart M
Breast; 2015 Nov; 24 Suppl 2():S143-8. PubMed ID: 26255196
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer.
Cadoo KA; Morris PG; Cowell EP; Patil S; Hudis CA; McArthur HL
Clin Breast Cancer; 2016 Dec; 16(6):487-493. PubMed ID: 27622751
[TBL] [Abstract][Full Text] [Related]
5. The evolving understanding of small HER2-positive breast cancers: matching management to outcomes.
Waks AG; Tolaney SM
Future Oncol; 2015; 11(24):3261-71. PubMed ID: 26634944
[TBL] [Abstract][Full Text] [Related]
6. Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.
Gullo G; Walsh N; Fennelly D; Bose R; Walshe J; Tryfonopoulos D; O'Mahony K; Hammond L; Silva N; McDonnell D; Ballot J; Quinn C; McDermott EW; Evoy D; Prichard R; Geraghty J; Amstrong J; Crown J
Br J Cancer; 2018 Aug; 119(3):374-380. PubMed ID: 29773838
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant regimens with trastuzumab administered for small HER2-positive breast cancer in routine clinical practice.
Antolín-Novoa S; Blanco-Campanario E; Antón A; Gallegos-Sancho MI; Pérez-Carrión R; Peláez I; Galán-Brotons A; de la Cruz-Merino L; Murías-Rosales A;
Clin Transl Oncol; 2015 Nov; 17(11):862-9. PubMed ID: 26103952
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
9. Benefit of adjuvant chemotherapy with or without trastuzumab in pT1ab node-negative human epidermal growth factor receptor 2-positive breast carcinomas: results of a national multi-institutional study.
de Nonneville A; Gonçalves A; Zemmour C; Classe JM; Cohen M; Lambaudie E; Reyal F; Scherer C; Muracciole X; Colombo PE; Giard S; Rouzier R; Villet R; Chopin N; Darai E; Garbay JR; Gimbergues P; Sabiani L; Coutant C; Sabatier R; Bertucci F; Boher JM; Houvenaeghel G
Breast Cancer Res Treat; 2017 Apr; 162(2):307-316. PubMed ID: 28155054
[TBL] [Abstract][Full Text] [Related]
10. Prognostic risk factors for treatment decision in pT1a,b N0M0 HER2-positive breast cancers.
Musolino A; Boggiani D; Sikokis A; Rimanti A; Pellegrino B; Vattiato R; Sgargi P; Falcini F; Caminiti C; Michiara M; Leonardi F
Cancer Treat Rev; 2016 Feb; 43():1-7. PubMed ID: 26827687
[TBL] [Abstract][Full Text] [Related]
11. T-DM1 in the Neo-Adjuvant Treatment of HER2-Positive Breast Cancer: Impact of the KRISTINE (TRIO-021) Trial.
Okines AF
Rev Recent Clin Trials; 2017; 12(3):216-222. PubMed ID: 28552047
[TBL] [Abstract][Full Text] [Related]
12. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
[TBL] [Abstract][Full Text] [Related]
13. Ten years of using adjuvant trastuzumab in breast cancer in Serbia - Single institution experience.
Cvetanovic A; Filipovic S; Zivkovic N; Popovic L; Kostic M; Djordjevic M; Karanikolic A; Krtinic D
J BUON; 2018; 23(2):353-360. PubMed ID: 29745076
[TBL] [Abstract][Full Text] [Related]
14. Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.
Perez EA; Ballman KV; Tenner KS; Thompson EA; Badve SS; Bailey H; Baehner FL
JAMA Oncol; 2016 Jan; 2(1):56-64. PubMed ID: 26469139
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
16. Singapore Cancer Network (SCAN) Guidelines for Adjuvant Trastuzumab Use in Early Stage HER2 Positive Breast Cancer.
Singapore Cancer Network (SCAN) Breast Cancer Workgroup
Ann Acad Med Singap; 2015 Oct; 44(10):360-7. PubMed ID: 26763053
[TBL] [Abstract][Full Text] [Related]
17. [Update: adjuvant trastuzumab in HER2 positive breast cancer].
Tahover E; Sonnenblick A; Peretz T; Katz D
Harefuah; 2012 Jan; 151(1):37-42, 61. PubMed ID: 22670500
[TBL] [Abstract][Full Text] [Related]
18. Escalating and de-escalating treatment in HER2-positive early breast cancer.
Joensuu H
Cancer Treat Rev; 2017 Jan; 52():1-11. PubMed ID: 27866067
[TBL] [Abstract][Full Text] [Related]
19. HER2-positive metastatic breast cancer: a changing scenario.
Mustacchi G; Biganzoli L; Pronzato P; Montemurro F; Dambrosio M; Minelli M; Molteni L; Scaltriti L
Crit Rev Oncol Hematol; 2015 Jul; 95(1):78-87. PubMed ID: 25748080
[TBL] [Abstract][Full Text] [Related]
20. Systemic therapy for early-stage HER2-positive breast cancers: time for a less-is-more approach?
Paplomata E; Nahta R; O'Regan RM
Cancer; 2015 Feb; 121(4):517-26. PubMed ID: 25346473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
